Maze Therapeutics Inc. reported its financial results for the first quarter of 2025, showing a cash and cash equivalents position of $294.4 million as of March 31, 2025, an increase from $196.8 million as of December 31, 2024. The company expects this cash position to fund its operations into the second half of 2027. Research and development expenses rose to $27.6 million in Q1 2025 from $21.9 million in the same period of 2024. This increase was mainly due to higher clinical trial expenses for MZE829 and MZE782, as well as personnel-related expenses. General and administrative expenses also increased, reaching $7.8 million in Q1 2025 compared to $6.1 million in Q1 2024, attributed to higher personnel and professional services fees. Maze Therapeutics reported a net loss of $32.8 million for the first quarter of 2025, slightly higher than the $32.5 million loss reported in the same quarter of the previous year. The company is actively progressing with its clinical programs, including the Phase 2 HORIZON trial of MZE829 for APOL1 Kidney Disease, with initial data expected in Q1 2026. Additionally, the Phase 1 trial of MZE782 is ongoing, with initial data anticipated in Q3 2025 to support Phase 2 trials in chronic kidney disease (CKD) and phenylketonuria (PKU). Maze's strong balance sheet positions it well to advance its pipeline and mission.